Nanoparticles for Cancer Drug Delivery
| Abstract |
|
|
Solid tumors have an acidic extracellular environment and an altered pH gradient across their cell compartments. Nanoparticles
responsive to the pH gradients are promising for cancer drug delivery. Such pH-responsive nanoparticles consist of a corona
and a core, one or both of which respond to the external pH to change their soluble/insoluble or charge states. Nanoparticles
whose coronas become positively charged or become soluble to make their targeting groups available for binding at the tumor
extracellular pH have been developed for promoting cellular targeting and internalization. Nanoparticles whose cores become
soluble or change their structures to release the carried drugs at the tumor extracellular pH or lysosomal pH have been developed
for fast drug release into the extracellular fluid or cytosol. Such pH-responsive nanoparticles have therapeutic advantages
over the conventional pH-insensitive counterparts.
Affiliation(s): (3) Soft Materials Laboratory, Department of Chemical and Petroleum Engineering, University of Wyoming, Laramie, WY, USA
(4) Department of Animal Science, University of Wyoming, Laramie, WY, USA
(4) Department of Animal Science, University of Wyoming, Laramie, WY, USA
Book Title: Drug Delivery Systems
Series: Methods in Molecular Biology | Volume: 437 | Pub. Date: Mar-07-2008 | Page Range: 183-216 | DOI: 10.1007/978-1-59745-210-6_10
Subject: Biotechnology
| References |
|
| 1. | American Cancer Society. Cancer facts and figures, 2006. Am Cancer Soc, 2006. |
| 2. | 2. Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Platinum compounds: a new class of potent antitumor agents. Nature
1969, 222, 385–386. |
| 3. | 3. Takahara, P. M.; Rosenzweig, A. C.; Frederick, C. A.; Lippard, S. J. Crystal structure of double-stranded DNA containing
the major adduct of the anticancer drug cisplatin. Nat. Rev. Drug Discov. 1995, 377, 649–652. |
| 4. | 4. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99, 2467–2498. |
| 5. | 5. Pinzani, V.; Bressolle, F.; Hang, I. J.; Galtier, M.; Blayac, J. P.; Balmes, P. Cisplatin-induced renal toxicity and toxicity-modulating
strategies: a review. Cancer Chemother. Pharmacol. 1994, 35, 1–9. |
| 6. | 6. Balch, C.; Huang, T. H.-M.; Brown, R.; Nephew, K. P. The epigenetics of ovarian cancer drug resistance and resensitization.
Am. J. Obstet. Gynecol. 2004, 191, 1552–1572. |
| 7. | American Cancer Society Inc. Cancer facts and figures, 2002. www.cancer.org. |
| 8. | 8. Hodge, J. W.; Tsang, K.-Y.; Poole, D. J.; Schlom, J. Vaccine strategies for the therapy of ovarian cancer. Gynecol. Oncol.
2003, 88, S97–S104. |
| 9. | 9. Greenlee, R. T.; Hill-Harmon, M. B.; Murray, T.; Thun, M. Cancer statistics, 2001. CA Cancer J. Clin. 2001, 51, 15–36. |
| 10. | 10. Agarwal, R.; Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3, 502–516. |
| 11. | 11. Pastan, I.; Gottesman, M. M. Multidrug resistance. Annu. Rev. Med. 1991, 42, 277–286. |
| 12. | 12. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53, 615–627. |
| 13. | 13. Vasey, P. A. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br. J. Cancer 2003, 89, S23–S28. |
| 14. | 14. Wang, G.; Reed, E.; Li, Q. Q. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer
[Review]. Oncol. Rep. 2004, 12, 955–965. |
| 15. | 15. Michael, M.; Doherty, M. M. Tumoral drug metabolism: overview and its implications for cancer therapy J. Clin. Oncol.
2005, 23, 205–229. |
| 16. | 16. Duvvuri, M.; Krise, J. P. Intracellular drug sequestration events associated with the emergence of multidrug resistance:
a mechanistic review. Front. Biosci. 2005, 10, 1499–1509. |
| 17. | 17. George, J. A.; Chen, T.; Taylor, C. C. Src tyrosine kinase and multidrug resistance protein-1 inhibitions act independently
but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res. 2005, 65, 10381–10388. |
| 18. | 18. Perry III, W. L.; Shepard, R. L.; Sampath, J.; Yaden, B.; Chin, W. W.; Iversen, P. W.; Jin, S.; Lesoon, A.; O'Brien, K.
A.; Peek, V. L.; Rolfe, M.; Shyjan, A.; Tighe, M.; Williamson, M.; Krishnan, V.; Moore, R. E.; Dantzig, A. H. Human splicing
factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed – a phenotype partially reversed
by selective estrogen receptor modulators. Cancer Res. 2005, 65, 6593–6600. |
| 19. | 19. Parker, R. J.; Eastman, A.; Bostick-Bruton, F.; Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is
associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 1991, 87, 772–777. |
| 20. | 20. Zhang, C.; Marme, A.; Wenger, T.; Gutwein, P.; Edler, L.; Rittgen, W.; Debatin, K.-M.; Altevogt, P.; Mattern, J.; Herr, I. Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int. J. Oncol. 2006, 28, 551–558. |
| 21. | 21. Macleod, K.; Mullen, P.; Sewell, J.; Rabiasz, G.; Lawrie, S.; Miller, E.; Smyth, J. F.; Langdon, S. P. Altered ErbB receptor
signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 2005, 65, 6789–6800. |
| 22. | 22. Bergom, C.; Gao, C.; Newman, P. J. Mechanisms of PECAM-1-mediated cytoprotection and implications for cancer cell survival.
Leuk Lymphoma 2005, 46, 1409–1421. |
| 23. | 23. Soengas, M. S.; Lowe, S. W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22, 3138–3151. |
| 24. | 24. Yakirevich, E.; Sabo, E.; Naroditsky, I.; Sova, Y.; Lavie, O.; Resnick, M. B. Multidrug resistance-related phenotype and
apoptosis-related protein expression in ovarian serous carcinomas. Gynecol. Oncol. 2006, 100, 152–159. |
| 25. | 25. Austin, D. L.; Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22, 7340–7358. |
| 26. | 26. Bogman, K.; Peyer, A. K.; Torok, M.; Kusters, E.; Drewe, J. HMG-CoA reductase inhibitors and P-glycoprotein modulation.
Br. J. Pharmacol. 2001, 132, 1183–1192. |
| 27. | 27. Glavinas, H.; Krajcsi, P.; Cserepes, J.; Sarkadi, B. The role of ABC transporters in drug resistance, metabolism, and
toxicity. Curr. Drug Deliv. 2004, 1, 27–42. |
| 28. | 28. Ross, D. D.; Doyle, L. A. Mining our ABCs: Pharmacogenomic approach for evaluating transporter function in cancer drug
resistance. Cancer Cell 2004, 6, 105–107. |
| 29. | 29. Keizer, H. G.; Schuurhuis, G. J.; Broxterman, H. J.; Lankelma, J.; Schoonen, W. G.; van Rijn, J.; Pinedo, H. M.; Joenje,
H. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased
P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res. 1989, 49, 2988–2993. |
| 30. | 30. Monsky, W. L.; Fukumura, D.; Gohongi, T.; Ancukiewcz, M.; Weich, H. A.; Torchilin, V. P.; Jain, R. K. Augmentation of
transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res.
1999, 59, 4129–4135. |
| 31. | 31. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular
drug targeting. Adv. Enzyme Regul. 2001, 41, 189–207. |
| 32. | 32. Maeda, H.; Seymour, L. W.; Miyamoto, Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics
in vivo. Bioconjug Chem. 1992, 3, 351–362. |
| 33. | 33. Jain, R. K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function.
J. Control. Release 2001, 74, 7–25. |
| 34. | 34. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport
pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95, 4607–4612. |
| 35. | 35. Yuan, F.; Dellian, M.; Fukumura, D.; Leuning, M.; Berk, D. D.; Torchilin, V. P.; Jain, R. K. Vascular permeability in
a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55, 3752–3756. |
| 36. | 36. Unezaki, S.; Maruyama, K.; Hosoda, J.-I.; Nagae, I.; Koyanagi, Y.; Nakata, M.; Ishida, O.; Iwatsuru, M.; Tsuchiya, S.
Direct measurement of the extravasation of poly(ethylene glycol)-coated liposomes into solid tumor tissue by in vivo fluorescence
microscopy. Int. J. Pharm. 1996, 144, 11–17. |
| 37. | 37. Yuan, F.; Lwunig, M.; Huang, S. K.; Berk, D. A.; Papahadjopoulos, D.; Jain, R. K. Microvascular permeability and interstitial
penetration of sterically stabilized (stealth) liposomes in a human tumour xenograft. Cancer Res. 1994, 54, 3352–3356. |
| 38. | 38. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. 2003, 2, 347–360. |
| 39. | 39. Satchi-Fainaro, R.; Duncan, R.; Barnes, C. M. Polymer therapeutics for cancer: current status and future challenges. Adv.
Polym. Sci. 2006, 193, 1–65. |
| 40. | 40. Thatte, S.; Datar, K.; Ottenbrite, R. M. Perspectives on: polymeric drugs and drug delivery systems. J. Bioact. Compat.
Polym. 2005, 20, 585–601. |
| 41. | 41. Qiu, L. Y.; Bae, Y. H. Polymer architecture and drug delivery. Pharm. Res. 2006, 23, 1–30. |
| 42. | 42. Majoros, I. J.; Myc, A.; Thomas, T.; Mehta, C. B.; Baker, J. R. Jr. PAMAMdendrimer-based multifunctional conjugate for
cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006, 7, 572–579. |
| 43. | 43. Patri, A. K.; Kukowska-Latallo, J. F.; Baker, J. R. Targeted drug delivery with dendrimers: comparison of the release
kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Deliv. Rev. 2005, 57, 2203–2214. |
| 44. | 44. Ambade, A. V.; Savariar, E. N.; Thayumanavan, S. Dendrimeric micelles for controlled drug release and targeted delivery.
Mol. Pharm. 2005, 2, 264–272. |
| 45. | 45. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nature Rev. Drug Discov. 2005, 4, 145–160. |
| 46. | 46. Sapra, P.; Tyagi, P.; Allen, T. M. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv. 2005, 2, 369–381. |
| 47. | 47. Torchilin, V. P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell. Mol. Life Sci. 2004, 61, 2549–2559. |
| 48. | 48. Kwon, G. S. Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier Syst. 2003, 20, 357–403. |
| 49. | 49. Kataoka, K. H. A.; Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance.
Adv. Drug Deliv. Rev. 2001, 47, 113–131. |
| 50. | 50. Torchilin, V. P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 2001, 73, 137–172. |
| 51. | 51. Labhasetwar, V.; Song, C.; Levy, R. J. Nanoparticle drug delivery system for restenosis. Adv. Drug Deliv. Rev. 1997, 24, 63–85. |
| 52. | 52. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002, 54, 631–651. |
| 53. | 53. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv.
Rev. 2003, 55, 329–347. |
| 54. | 54. Kim, Y.; Dalhaimer, P.; Christian, D. A.; Discher, D. E. Polymeric worm micelles as nano-carriers for drug delivery. Nanotechnology
2005, 16, 484–491. |
| 55. | 55. Seymour, L. W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst.
1992, 9, 135–187. |
| 56. | 56. Lu, Y.; Low, P. S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 2002, 54 675–693. |
| 57. | 57. Lu, Y.; Low, P. S. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects.
J. Control. Release 2003, 91 17–29. |
| 58. | 58. Gosselin, M. A.; Lee, R. J. Folate receptor-targeted liposomes as vectors for therapeutic agents. Biotechnol. Annu. Rev.
2002, 8, 103–131. |
| 59. | 59. Weitman, S. D.; Lark, R. H., Coney, L. R.; Fort, D. W.; Frasca, V.; Zurawski Jr., V. R.; Kamen, B. A. Distribution of
the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992, 52, 3396–3401. |
| 60. | 60. Ross, J. F.; Chaudhuri, P. K.; Ratnam, M. Differential regulation of folate receptor forms in normal and malignant tissues
in vivo and in established cell lines. Physiologic and clinical Implications. Cancer 1994, 73 2432–2443. |
| 61. | 61. Li, P. Y.; Del Vecchio, S.; Fonti, R.; Carriero, M. V.; Potena, M. I.; Botti, G.; Miotti, S.; Lastoria, S.; Menard, S.;
Colnaghi, M. I.; Salvatore, M. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by
in vitro quantitative autoradiography. J. Nucl. Med. 1996, 37, 665–672. |
| 62. | 62. Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M. Overexpression of folate binding protein in
ovarian cancers. Int. J. Cancer 1997, 74, 193–198. |
| 63. | 63. Corona, G.; Giannini, F.; Fabris, M.; Toffoli, G.; Boiocchi, M. Role of folate receptor and reduced folate carrier in
the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int. J. Cancer 1998, 75, 125–133. |
| 64. | 64. Atkinson, S. F.; Bettinger, T.; Seymour, L. W.; Behr, J.-P.; Ward, C. M. Conjugation of folate via gelonin carbohydrate
residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J.
Bio. Chem. 2001, 276, 27930–27935. |
| 65. | 65. Garin-Chesa, P.; Campbell, I.; Saigo, P. E.; Lewis Jr., J. L.; Old, L. J.; Rettig, W. J. Trophoblast and ovarian cancer
antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am.
J. Pathol. 1993, 142, 557–567. |
| 66. | 66. Wang, S.; Lee, R. J.; Cauchon, G.; Gorenstein, D. G.; Low, P. S. Delivery of antisense oligodeoxyribonucleotides against
the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.
Proc. Natl. Acad. Sci. USA 1995, 92, 3318–3322. |
| 67. | 67. Leamon, C. P.; Low, P. S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today 2001, 6, 44–51. |
| 68. | 68. Leamon, C. P.; Reddy, J. A. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. 2004, 56, 1127–1141. |
| 69. | 69. Kennedy, M. D.; Jallad, K. N.; Lu, J.; Low, P. S.; Ben-Amotz, D. Evaluation of folate conjugate uptake and transport by
the choroid plexus of mice. Pharm. Res. 2003, 20, 714–719. |
| 70. | 70. Sudimack, J.; Lee, R. J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 2000, 41, 147–162. |
| 71. | 71. Hilgenbrink, A. R.; Low, P. S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci.
2005, 94, 2135–2146. |
| 72. | 72. Paranjpe, P. V.; Stein, S.; Sinko, P. J. Tumor-targeted and activated bioconjugates for improved camptothecin delivery.
Anticancer Drugs 2005, 16, 763–775. |
| 73. | 73. Cavallaro, G.; Mariano, L.; Salmaso, S.; Caliceti, P.; Gaetano, G. Folate-mediated targeting of polymeric conjugates of
gemcitabine. Int. J. Pharm. 2006, 307, 258–269. |
| 74. | 74. Bajo, A. M.; Schally, A. V.; Halmos, G.; Nagy, A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone
analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin. Cancer Res. 2003, 9, 3742–3748. |
| 75. | 75. Qi, L.; Nett, T. M.; Allen, M. C.; Sha, X.; Harrison, G. S.; Frederick, B. A.; Crawford, E. D.; Glode, L. M. Binding and
cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. Cancer
Res. 2004, 64, 2090–2095. |
| 76. | 76. Danila, D. C.; Schally, A. V.; Nagy, A.; Alexander, J. M. Selective induction of apoptosis by the cytotoxic analog AN-207
in cells expressing recombinant receptor for luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 1999, 96, 669–673. |
| 77. | 77. Dharap, S. S.; Qiu, B.; Williams, G. C.; Sinko, P.; Stein, S.; Minko, T. Molecular targeting of drug delivery systems
to ovarian cancer by BH3 and LH-RH peptides. J. Control. Release 2003, 91, 61–73. |
| 78. | 78. Dharap, S. S.; Wang, Y.; Chandna, P.; Khandare, J. J.; Qiu, B.; Gunaseelan, S.; Sinko, P. J.; Stein, S.; Farmanfarmaian,
A.; Minko, T. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. USA 2005, 102, 12962–12967. |
| 79. | 79. Sheff, D. Endosomes as a route for drug delivery in the real world. Adv. Drug Deliv. Rev. 2004, 56, 927–930. |
| 80. | 80. van Vlerken, L. E.; Amiji, M. M. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin.
Drug Deliv. 2006, 3, 205–216. |
| 81. | 81. Kommareddy, S.; Tiwari, S. B.; Amiji, M. M. Long-circulating polymeric nanovectors for tumor-selective gene delivery.
Technol. Cancer Res. Treat. 2005, 4, 615–625. |
| 82. | 82. Hans, M. L.; Lowman, A. M. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater.
Sci. 2002, 6, 319–327. |
| 83. | 83. Gref, R. M. Y.; Peracchia, M. T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres.
Science 1994, 263, 1600–1603. |
| 84. | 84. Torchilin, V. P. Block copolymer micelles as a solution for drug delivery problems. Expert Opin. Ther. Patents 2005, 15,
63–75. |
| 85. | 85. Torchilin, V. P.; Weissig, V. Polymeric micelles for the delivery of poorly soluble drugs. ACS Symp. Ser. 2000, 752, 297–313. |
| 86. | 86. Bogdanov Jr., A.; Wright, S. C.; Marecos, E. M.; Bogdanova, A.; Martin, C.; Petherick, P.; Weissleder, R. A long-circulating
copolymer in “passive targeting” to solid tumors. J. Drug Target 1997, 4, 321–330. |
| 87. | 87. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Longcirculating and target-specific nanoparticles: theory to practice. Pharmacol.
Rev. 2001, 53, 283–318. |
| 88. | 88. Kaul, G.; Amiji, M. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery.
Pharm. Res. 2002, 19, 1061–1067. |
| 89. | 89. Kwon, G. S.; Kataoka, K. Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Deliv. Rev. 1995, 16 295–309. |
| 90. | 90. Savic, R.; Eisenberg, A.; Maysinger, D. Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell
interactions. J. Drug Target. 2006, 14, 343–355. |
| 91. | 91. Torchilin, V. P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Ann. Rev. Biomed.
Eng. 2006, 8, 343–375. |
| 92. | 92. Yokoyama, M. Polymeric micelle drug carriers for tumor targeting. ACS Symp. Ser. 2006, 923, 27–39. |
| 93. | 93. Yokoyama, M.; Okano, T.; Sakurai, Y.; Suwa, S.; Kataoka, K. Introduction of cisplatin into polymeric micelle. J. Control.
Release 1996, 39, 351–356. |
| 94. | 94. Cabral, H.; Nishiyama, N.; Okazaki, S.; Koyama, H.; Kataoka, K. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II)
(DACHPt)-loaded polymeric micelles. J. Control. Release 2005, 101, 223–232. |
| 95. | 95. Nishiyama, N.; Okazaki, S.; Cabral, H.; Miyamoto, M.; Kato, Y.; Sugiyama, Y.; Nishio, K.; Matsumura, Y.; Kataoka, K. Novel
cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003, 63, 8977–8983. |
| 96. | 96. Xu, P.; Van Kirk, E. A.; Li, S.; Murdoch, W. J.; Ren, J.; Hussain, M. D.; Radosz, M.; Shen, Y. Highly stable core-surface-crosslinked
nanoparticles as cisplatin carriers for cancer chemotherapy. Colloids Surf. B: Biointerface 2006, 48, 50–57. |
| 97. | 97. Xu, P.; Van Kirk, E. A.; Murdoch, W. J.; Zhan, Y.; Isaak, D. D.; Radosz, M.; Shen, Y. Anticancer efficacies of cisplatin-releasing
pH-responsive nanoparticles. Biomacromolecules 2006, 7, 829–835. |
| 98. | 98. Uchino, H.; Matsumura, Y.; Negishi, T.; Koizumi, F.; Hayashi, T.; Honda, T.; Nishiyama, N.; Kataoka, K.; Naito, S.; Kakizoe,
T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.
Br. J. Cancer 2005, 93, 678–687. |
| 99. | 99. Lee, E. S.; Na, K.; Bae, Y. H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
J. Control. Release 2005, 103, 405–418. |
| 100. | 100. Aouali, N.; Morjani, H.; Trussardi, A.; Soma, E.; Giroux, B.; Manfait, M. Enhanced cytotoxicity and nuclear accumulation
of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1. Int. J. Oncol. 2003, 23, 1195–1201. |
| 101. | 101. Kataoka, K.; Matsumoto, T.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Fukushima, S.; Okamoto, K.; Kwon, G. S. Doxorubicin-loaded
poly(ethylene glycol)-poly([beta]-benzyl-aspartate) copolymer micelles: their pharmaceutical characteristics and biological
significance. J. Control. Release 2000, 64, 143–153. |
| 102. | 102. Kwon, G.; Naito, M.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Kataoka, K. Block copolymer micelles for drug delivery: loading
and release of doxorubicin. J. Control. Release 1997, 48 195–201. |
| 103. | 103. Bennis, S.; Chapey, C.; Couvreur, P.; Robert, J. Enhanced cytotoxicity of doxorubicin encapsulated in polyhexylcyanoacrylate
nanospheres against multi-drug-resistant tumour cells in culture. Eur. J. Cancer 1994, 30A, 89–93. |
| 104. | 104. Kawano, K.; Watanabe, M.; Yamamoto, T.; Yokoyama, M.; Opanasopit, P.; Okano, T.; Maitani, Y. Enhanced antitumor effect
of camptothecin loaded in long-circulating polymeric micelles. J. Control. Release 2006, 112, 329–332. |
| 105. | 105. Opanasopit, P.; Yokoyama, M.; Watanabe, M.; Kawano, K.; Maitani, Y.; Okano, T. Influence of serum and albumins from different
species on stability of camptothecin-loaded micelles. J. Control. Release 2005, 104, 313–321. |
| 106. | 106. Onishi, H.; Machida, Y. Macromolecular and nanotechnological modification of camptothecin and its analogs to improve
the efficacy. Curr. Drug Discov. Technol. 2005, 2, 169–183. |
| 107. | 107. Zhang, L.; Hu, Y.; Jiang, X.; Yang, C.; Lu, W.; Yang, Y. H. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide)
nanoparticles and their biodistribution in mice. J. Control. Release 2004, 96, 135–148. |
| 108. | 108. Tyner, K. M.; Schiffman, S. R.; Giannelis, E. P. Nanobiohybrids as delivery vehicles for camptothecin. J. Control. Release
2004, 95, 501–514. |
| 109. | 109. Miura, H.; Onishi, H.; Sasatsu, M.; Machida, Y. Antitumor characteristics of methoxypolyethylene glycol-poly(dl-lactic
acid) nanoparticles containing camptothecin. J. Control. Release 2004, 97, 101–113. |
| 110. | 110. Williams, J.; Lansdown, R.; Sweitzer, R.; Romanowski, M.; LaBell, R.; Ramaswami, R.; Unger, E. Nanoparticle drug delivery
system for intravenous delivery of topoisomerase inhibitors. J. Control. Release 2003, 91, 167–172. |
| 111. | 111. Koziara, J. M.; Whisman, T. R.; Tseng, M. T.; Mumper, R. J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant
human colorectal tumors. J. Control. Release 2006, 112, 312–319. |
| 112. | 112. Xu, Z.; Gu, W.; Huang, J.; Hong, S.; Zhou, Z.; Yang, Y.; Yan, Z.; Li, Y. In vitro and in vivo evaluation of actively
targetable nanoparticles for paclitaxel delivery. Int. J. Pharm. 2005, 288, 361–368. |
| 113. | 113. Soga, O.; van Nostrum, C. F.; Fens, M.; Rijcken, C. J. F.; Schiffelers, R. M.; Storm, G.; Hennink, W. E. Thermosensitive
and biodegradable polymeric micelles for paclitaxel delivery. J. Control. Release 2005, 103, 341–353. |
| 114. | 114. Park, E. K.; Kim, S. Y.; Lee, S. B.; Lee, Y. M. Folate-conjugated methoxy poly(ethylene glycol)/poly(vepsiln-caprolactone)
amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J. Control. Release 2005, 109, 158–168. |
| 115. | 115. Potineni, A.; Lynn, D. M.; Langer, R.; Amiji, M. M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles
as a pH-sensitive biodegradable system for paclitaxel delivery. J. Control. Release 2003, 86, 223–234. |
| 116. | 116. Yokoyama, M.; Fukushima, S.; Uehara, R.; Okamoto, K.; Kataoka, K.; Sakurai, Y.; Okano, T. Characterization of physical
entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor.
J. Control. Release 1998, 50, 79–92. |





















